nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-E08014D7·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Physiology·Basis: Full text·Type: Cross-sectional study

Aβ- and tau-associated neuroinflammatory signatures in Alzheimer's disease.

Bellaver et al.Bellaver, Povala, De Bastiani et al.·2026·Alzheimer's & dementia (New York, N. Y.)·10.1002/trc2.70275 ↗

Primary claim

we identified distinct neuroinflammatory signatures related to broad downregulation of innate and adaptive immune proteins during Aβ accumulation, and upregulation of adaptive immune pathways with tau spread

Supported · PET-staged cross-sectional contrasts support distinct associations but not within-person temporal progression
In brief

PET-staged CSF proteomics identifies distinct inflammatory signatures, but cross-sectional contrasts cannot establish the claimed temporal waves or treatment strategy.

ReliabilityConcerns4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

INTRODUCTION: Neuroinflammation is increasingly recognized as a key contributor to Alzheimer's disease (AD) progression, with distinct responses linked to amyloid beta (Aβ) and tau pathology. Two detrimental waves of neuroinflammation have been proposed, the first during early Aβ accumulation, and the second during widespread tau deposition. However, the neuroinflammatory signatures associated with each phase remain unclear.

METHODS: We studied 63 individuals who underwent Aβ and tau positron emission tomography imaging along with cerebrospinal fluid profiling of 368 inflammation-related proteins. Protein contrasts between cognitively unimpaired Aβ-negative and Aβ-positive individuals defined the signature of the Aβ phase, while comparisons between cognitively impaired Aβ-positive individuals with early versus late tau pathology characterized the tau phase. Gene Ontology enrichment identified biological processes associated with differentially expressed proteins.

RESULTS: During the Aβ phase, 34 proteins were downregulated and mapped to 157 biological processes, including Toll-like receptor signaling, nuclear factor kappa beta activation, and cytokine production. The tau phase showed upregulation of 23 proteins associated with 82 biological processes enriched in adaptive immune responses. A set of 48 biological processes and three proteins including interleukin 4 receptor, cystosolic phospholipidase A2, and secretoglobin family 3A member 2 showed opposite regulation patterns, being downregulated in the Aβ phase and upregulated in the tau phase.

DISCUSSION: Our results revealed distinct neuroinflammatory signatures and biological processes associated with Aβ- and tau-dominant stages of AD. The reversal in protein expression patterns across these stages underscores the need for stage-specific neuroimmune therapeutic strategies.

Key Claims

Primary finding · Supported

we identified distinct neuroinflammatory signatures related to broad downregulation of innate and adaptive immune proteins during Aβ accumulation, and upregulation of adaptive immune pathways with tau spread

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

PET-staged cross-sectional contrasts support distinct associations but not within-person temporal progression

Research in Context, Interpretation
Quote verified
Secondary · Tentative

During the Aβ phase, 34 proteins were downregulated and mapped to 157 biological processes.

small cross-sectional comparison with a lenient enrichment threshold and unreconciled pathway totals

Abstract, Results
Quote verified
Secondary · Tentative

The tau phase showed upregulation of 23 proteins associated with 82 biological processes enriched in adaptive immune responses.

protein direction is reported, but pathway breadth depends on lenient enrichment and inconsistent process totals

Abstract, Results
Quote verified
Secondary · Supported

A set of 48 biological processes and three proteins including interleukin 4 receptor, cystosolic phospholipase A2, and secretoglobin family 3A member 2 showed opposite regulation patterns.

directional differences are reported across separate cross-sectional contrasts rather than a directly tested reversal

Abstract, Results
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

PET-anchored inflammatory proteomic staging

The study combines Aβ and tau PET with a 368-analyte CSF inflammatory panel, allowing molecular comparisons across explicitly defined pathology groups rather than clinical categories alone.

↳ Abstract, Methods, Study Population and CSF Proteomics

#methodological rigour

Transparent imaging and group definitions

Aβ positivity, tau Braak-like staging, PET acquisition, and the four analysis groups are described with explicit thresholds and sample sizes.

↳ Methods, PET and MRI Acquisition and Processing; Statistical Analysis

#application pathway

Concrete candidates for follow-up

IL4R, PLA2G4A, and SCGB3A2 provide named candidates for replication, alongside directional immune-process hypotheses that can be tested longitudinally.

↳ Abstract Results; Results, “Unique and shared inflammatory processes”

Limitations

#methodological rigour

Cross-sectional contrasts framed as waves

The Aβ and tau signatures arise from different between-group comparisons, not repeated observations of the same individuals. The Discussion nevertheless describes two temporal waves and a transition between them.

↳ Methods, Statistical Analysis; Discussion, opening and limitations paragraphs

#methodological rigour

Pathway totals do not reconcile

The reported 157 Aβ-phase and 82 tau-phase processes conflict with unique-plus-shared totals of 150 and 88. This inconsistency directly affects the pathway-level narrative.

↳ Results, “Aβ- and tau-associated neuroinflammatory proteins” and “Unique and shared inflammatory processes”

#positioning

Therapeutic conclusions exceed evidence

The paper proposes stage-specific immune targets and states that successful immunomodulation will require stage-specific strategies, despite acknowledging that longitudinal validation is critical.

↳ Discussion, therapeutic interpretation, limitations, and final paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

The paper’s principal advance is the integration of PET-defined Aβ and tau groups with targeted CSF inflammatory proteomics. Protein-level directions are more defensible than the pathway breadth because the q<0.2 enrichment threshold is liberal and the reported process totals do not reconcile with the unique and shared counts. The major methodological constraint is that two different cross-sectional contrasts are interpreted as successive waves and as a reversal, without a direct longitudinal or interaction test. The Discussion then extends these associations to causal mechanisms and stage-specific treatment recommendations despite explicitly stating that longitudinal confirmation and larger validation are needed.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.7±0.2

Contribution
3.5

The study meaningfully combines PET-defined Aβ and tau groupings with a 368-protein CSF inflammatory panel, extending prior clinically staged proteomic work. The advance remains preliminary because it rests on small cross-sectional subgroup contrasts and an informal comparison of directions across different populations.

Abstract, Methods; Results, “Aβ- and tau-associated neuroinflammatory proteins”

“distinct neuroinflammatory signatures and biological processes associated with Aβ- and tau-dominant stages of AD”

Methodological Rigour
2.0

PET thresholds, the Olink platform, age/sex-adjusted linear models, and protein-level BH correction are described, but the two cross-sectional contrasts cannot identify a within-person transition. Causal and therapeutic interpretations compound this temporality problem, while small groups, limited adjustment, liberal pathway enrichment, and unclear QC introduce further uncertainty.

Methods, Statistical Analysis and CSF Proteomics; Discussion, paragraphs 1–5

“early Aβ pathology induces a broad downregulation”

Reporting
3.3

The paper follows a coherent progression from staging rationale through protein and pathway results. Its central language nevertheless turns separate cross-sectional contrasts into “two waves” and strong treatment implications, leading readers beyond what the design establishes.

Abstract; Discussion, opening and final paragraphs

“revealed two waves of neuroinflammation in AD”

Positioning
2.8

The Discussion engages PET, proteomic, transcriptomic, animal, and post-mortem research and expressly acknowledges the cross-sectional design, modest sample, and restricted panel. The final claim that successful immunomodulation will require stage-specific strategies contradicts the stated need to confirm the transition longitudinally.

Discussion, literature synthesis, limitations paragraph, and final paragraph

“longitudinal analysis will be critical to confirm”

Reliability

Concerns4 of 4 checks


Results checkConcern
  • During the Aβ phase, 34 proteins were downregulated and mapped to 157 biological processes: "In the Aβ phase, we observed downregulation of 34 inflammatory proteins and 157 GO processes in Aβ‐positive individuals, spanning Toll‐like receptor signaling, NFκB activation, and T‐cell differentiation." (Discussion, paragraph 2) vs "We found 102 biological processes uniquely enriched in the Aβ phase and 40 uniquely enriched in the tau phase (Figure 3; Table S2). Forty‐eight inflammation‐related biological processes were common to the Aβ and tau phases all of them being downregulated in the Aβ phase and upregulated in the tau phase (Figure 3; Table S2)." (Results, Unique and shared inflammatory processes between Aβ and tau phases of AD). The reported partition gives 102 unique Aβ-phase processes plus 48 shared processes, totaling 150 rather than 157. → Changes the size materially
  • The tau phase showed upregulation of 23 proteins associated with 82 biological processes enriched in adaptive immune responses: "In the tau phase, the presence of widespread tau pathology is marked by the rise of 23 proteins and upregulation of 82 biological processes." (Discussion, paragraph 3) vs "We found 102 biological processes uniquely enriched in the Aβ phase and 40 uniquely enriched in the tau phase (Figure 3; Table S2). Forty‐eight inflammation‐related biological processes were common to the Aβ and tau phases all of them being downregulated in the Aβ phase and upregulated in the tau phase (Figure 3; Table S2)." (Results, Unique and shared inflammatory processes between Aβ and tau phases of AD). The reported partition gives 40 unique tau-phase processes plus 48 shared processes, totaling 88 rather than 82. → Changes the size materially
Reporting and transparencyNoted

Reporting issues concern the enrichment threshold and its confidence interpretation, handling of excluded protein measurements, and the SC3GBA2 protein-name typo; their correction does not establish a change in the protein-level results.

Conflict of interest: declared · Ethics approval: declared · Data availability: not stated · Code availability: not stated

Reference IntegrityClean

27 references in manuscript 27 of 27 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim rests on a cross-sectional observational comparison in a single 63-person cohort with no longitudinal or independent validation of the phase-specific signatures.

From the paper
“serve as readily accessible endpoints for trials that target neuroinflammatory pathways”

The paper names who would use the findings (clinical trials targeting neuroinflammatory pathways) and for what purpose (accessible endpoints and stage-specific treatment stratification), but not a specific decision or setting.

Pathway

Drug developers and clinical trial teams could use the stage-specific CSF protein signatures to stratify AD patients and time immunomodulatory therapies to the Aβ or tau phase.

Barrier

The signatures come from a small, single-site, cross-sectional cohort and need longitudinal confirmation in large independent studies before guiding trials or treatment.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →